Bharat Rasayan Limited has informed the Exchange regarding Board meeting held on February 12, 2026.
BHARATRAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts less than Nifty Microcap 250 and 3.6 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bharat Rasayan, a single-segment pesticides company, reported standalone revenue from operations of ₹270.46 crore for Q3 FY26, up about 5.5% year-on-year from ₹256.40 crore in Q3 FY25. For the nine months ended December 31, 2025, standalone revenue rose to ₹933.82 crore from ₹866.47 crore, roughly 7.8% growth. Standalone profit after tax for Q3 was ₹33.99 crore (vs ₹29.69 crore, up ~14.5%) and ₹103.81 crore for 9M (vs ₹96.64 crore, up ~7.4%). Standalone operating margin expanded to 17.25% in Q3 and 16.85% for 9M, compared with 16.63% and 15.74% a year earlier. Consolidated PAT for Q3 was largely flat at ₹40.03 crore, while 9M consolidated PAT fell about 7% to ₹107.57 crore due to lower share of profit from its joint venture (Nissan Bharat Rasayan) and a small exceptional charge of ₹1.49 crore. During the quarter, shareholders approved a 1:1 bonus issue and a share split from ₹10 to ₹5 per share, doubling the share count to 1,66,21,072 shares. The auditor (B.K. Goel & Associates) issued an unqualified limited review report.
Modestly positive for shareholders on a standalone basis given steady revenue growth, profit growth, and improving operating margins, though the consolidated picture is softer because of weaker joint venture contribution. The 1:1 bonus issue and share split improve retail liquidity but do not change underlying value. Ongoing insurance claim at the Dahej plant remains a watchpoint.